S100A8 and S100A9 in Cancer

Yu Chen; Yuzhen Ouyang; Zhixin Li; Xiufang Wang; Jian Ma

doi:10.1016/j.bbcan.2023.188891

S100A8 and S100A9 in Cancer

Biochim Biophys Acta Rev Cancer. 2023 May;1878(3):188891. doi: 10.1016/j.bbcan.2023.188891. Epub 2023 Mar 29.

Authors

Yu Chen¹, Yuzhen Ouyang², Zhixin Li³, Xiufang Wang³, Jian Ma⁴

Affiliations

¹ Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China; Cancer Research Institute, School of Basic Medicine Sciences, Xiangya School of Medicine, Central South University, Changsha, China; Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
² Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China; Cancer Research Institute, School of Basic Medicine Sciences, Xiangya School of Medicine, Central South University, Changsha, China; Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.
³ Cancer Research Institute, School of Basic Medicine Sciences, Xiangya School of Medicine, Central South University, Changsha, China.
⁴ Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China; Cancer Research Institute, School of Basic Medicine Sciences, Xiangya School of Medicine, Central South University, Changsha, China; Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Nonresolving Inflammation and Cancer, and Hunan Key Laboratory of Cancer Metabolism, Changsha, China. Electronic address: majian@csu.edu.cn.

PMID: 37001615
DOI: 10.1016/j.bbcan.2023.188891

Abstract

S100A8 and S100A9 are Ca²⁺ binding proteins that belong to the S100 family. Primarily expressed in neutrophils and monocytes, S100A8 and S100A9 play critical roles in modulating various inflammatory responses and inflammation-associated diseases. Forming a common heterodimer structure S100A8/A9, S100A8 and S100A9 are widely reported to participate in multiple signaling pathways in tumor cells. Meanwhile, S100A8/A9, S100A8, and S100A9, mainly as promoters, contribute to tumor development, growth and metastasis by interfering with tumor metabolism and the microenvironment. In recent years, the potential of S100A8/A9, S100A9, and S100A8 as tumor diagnostic or prognostic biomarkers has also been demonstrated. In addition, an increasing number of potential therapies targeting S100A8/A9 and related signaling pathways have emerged. In this review, we will first expound on the characteristics of S100A8/A9, S100A9, and S100A8 in-depth, focus on their interactions with tumor cells and microenvironments, and then discuss their clinical applications as biomarkers and therapeutic targets. We also highlight current limitations and look into the future of S100A8/A9 targeted anti-cancer therapy.

Keywords: Anti-cancer therapy; Biomarkers; Cancer; Cancer metabolism; Immune microenvironment; S100A8/A9.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Calgranulin A* / metabolism
Calgranulin B / genetics
Calgranulin B / metabolism
Humans
Neoplasms* / genetics
Signal Transduction
Tumor Microenvironment

Substances

Calgranulin A
Calgranulin B
Biomarkers